International Journal of Clinical Oncology

, Volume 23, Issue 1, pp 73–80 | Cite as

Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer

  • Tomoya Yokota
  • Takushi Yasuda
  • Hiroyuki Kato
  • Isao Nozaki
  • Hiroshi Sato
  • Yoshinori Miyata
  • Yoshifumi Kuroki
  • Ken Kato
  • Yasuo Hamamoto
  • Yasuhiro Tsubosa
  • Hirofumi Ogawa
  • Yoshinori Ito
  • Yuko Kitagawa
Original Article



We conducted a multicenter phase II trial assessing chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced, unresectable esophageal cancer. The aim of this study was to validate the concordance of clinical T diagnosis among physicians in the cases of this trial.


Computed tomography scans and esophagoscopic images of 48 patients taken at baseline were centrally reviewed by 6 senior physicians with experience in esophageal oncology. Individual reviewers voted for definitive T4, relative T4, relative T3, or definitive T3. Discordant diagnoses between reviewers were resolved by the majority opinion. The reviewers were blinded to patient clinical outcome data and to the vote of the other reviewers.


Ninety percent of cases were diagnosed as clinical T4 by investigators, while 33.3–75.0% (median 70.8%) of cases were judged to be T4 by 6 reviewers. Discordant diagnosis between investigators and reviewers occurred in 33% (16/48) of all cases (Cohen’s kappa coefficient 0.0519), including 12 cases where curative resection was considered possible (48%, n = 25) and 4 cases where curative resection was considered impossible (17%, n = 23). Critical discordance (one reviewer voted for definitive T3 but the other voted for definitive T4, and vice versa) between reviewers occurred in 0–12.5% of cases (median 2.1%).


There were inter-observer variations in clinical diagnosis of the T category of locally advanced, unresectable esophageal cancer. Accurate clinical diagnosis of T classification is required for determining the optimum treatment for each patient.


Esophageal squamous cell carcinoma Clinical T diagnosis Central review Concordance 



The authors are grateful to Tella Imaging Technology and Alliance Network (TITAN Inc.). This study was supported by Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (15652916). The authors are grateful to Dr. Takashi Ichimura, Dr. Mariko Ogura, Dr. Daisuke Takahari (Cancer Institute Hospital of Japanese Foundation for Cancer Research), Dr. Fumihiko Kato, Dr. Satoshi Matsuda (Keio University School of Medicine), Dr. Natsuko Okita, Dr. Satoru Iwasa, Dr. Atsuo Takashima, Dr. Yoshitaka Honma (National Cancer Center Hospital), Dr. Takako Yoshii (Saitama Cancer Center), Dr. Akiko Todaka, Dr. Nozomu Machida, Dr. Takahiro Tsushima (Shizuoka Cancer Center), Dr. Keiko Minashi (Chiba Cancer Center), Dr. Tetsushi Terasawa, Dr. Hitoshi Nishitani (Osaka Medical College), Dr. Kazuhiko Yamada (National Center for Global Health and Medicine), Dr. Kentaro Kawakami (Tochigi Cancer Center) for submission of CT scans and esophagoscopic images.

Compliance with ethical standards

Conflict of interest

Dr. Yuko Kitagawa has received research funding from Takeda Pharmaceutical Co., Ltd, Kyowa Hakko Kirin Co., Ltd, and Yakult Honsha Co., Ltd. Dr. Ken Kato has received research funding from ONO, MSD, and Shionogi.


  1. 1.
    Rustgi AK, El-Serag HB (2014) Esophageal carcinoma. N Engl J Med 371:2499–2509CrossRefPubMedGoogle Scholar
  2. 2.
    Abe S, Tachibana M, Shimokawa T et al (1989) Surgical treatment of advanced carcinoma of the esophagus. Surg Gynecol Obstet 168:115–120PubMedGoogle Scholar
  3. 3.
    Daly JM, Karnell LH, Menck HR (1996) National cancer data base report on esophageal carcinoma. Cancer 78:1820–1828CrossRefPubMedGoogle Scholar
  4. 4.
    van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084CrossRefPubMedGoogle Scholar
  5. 5.
    NCCN Clinical Practice Guidelines in Oncology (2017), Esophageal and esophagogastric junction cancers, version 1Google Scholar
  6. 6.
    Yokota T, Kato K, Hamamoto Y et al (2016) Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Br J Cancer 115:1328–1334CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Picus D, Balfe DM, Koehler RE et al (1983) CT in the staging of esophageal carcinoma. Radiology 146:433–438CrossRefPubMedGoogle Scholar
  8. 8.
    Kumbasar B (2002) Carcinoma of esophagus: radiologic diagnosis and staging. Eur J Radiol 42:170–180CrossRefPubMedGoogle Scholar
  9. 9.
    Yokota T, Hatooka S, Ura T et al (2011) Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res 31:3535–3541PubMedGoogle Scholar
  10. 10.
    Sobin LH, Wittekind C (2009) TNM classification of malignant tumors (UICC), 7th edn, Wiley-Blackwell, UK.
  11. 11.
    Yamabe Y, Kuroki Y, Ishikawa T, Miyakawa K, Kuroki S, Sekiguchi R et al (2008) Tumor staging of advanced esophageal cancer: combination of double-contrast esophagography and contrast-enhanced CT. Am J Roentgenol 191:753–757CrossRefGoogle Scholar
  12. 12.
    Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74CrossRefPubMedGoogle Scholar
  13. 13.
    Quint LE, Glazer GM, Orringer MB et al (1985) Esophageal carcinoma: CT findings. Radiology 155:171–175CrossRefPubMedGoogle Scholar
  14. 14.
    Griffin Y (2016) Esophageal cancer: role of imaging in primary staging and response assessment post neoadjuvant therapy. Semin Ultrasound CT MR 37:339–351CrossRefPubMedGoogle Scholar
  15. 15.
    Kato H, Miyazaki T, Nakajima M et al (2005) The incremental effect of PET on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148–156CrossRefPubMedGoogle Scholar
  16. 16.
    Liberman M, Hanna N, Duranceau A et al (2013) Endobronchial ultrasonography added to endoscopic ultrasonography improves staging in esophageal cancer. Ann Thorac Surg 96:232–236CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Tomoya Yokota
    • 1
  • Takushi Yasuda
    • 2
  • Hiroyuki Kato
    • 3
  • Isao Nozaki
    • 4
  • Hiroshi Sato
    • 5
  • Yoshinori Miyata
    • 6
  • Yoshifumi Kuroki
    • 7
  • Ken Kato
    • 8
  • Yasuo Hamamoto
    • 9
  • Yasuhiro Tsubosa
    • 10
  • Hirofumi Ogawa
    • 11
  • Yoshinori Ito
    • 12
  • Yuko Kitagawa
    • 13
  1. 1.Division of Gastrointestinal OncologyShizuoka Cancer CenterShizuokaJapan
  2. 2.Department of Surgery, Faculty of MedicineKinki UniversityOsakasayamaJapan
  3. 3.First Department of SurgeryDokkyo Medical UniversityShimotsugaJapan
  4. 4.Department of SurgeryShikoku Cancer Center HospitalMatsuyamaJapan
  5. 5.Division of Upper Gastrointestinal Tract, Department of SurgerySaitama Medical University International Medical CenterSaitamaJapan
  6. 6.Department of Medical OncologySaku Central Hospital Advanced Care CenterSakuJapan
  7. 7.Department of Radiology, Faculty of MedicineFukuoka UniversityFukuokaJapan
  8. 8.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan
  9. 9.Division of Gastroenterology and HepatologyKeio University School of MedicineTokyoJapan
  10. 10.Division of Esophageal SurgeryShizuoka Cancer CenterSunto-gunJapan
  11. 11.Division of Radiation OncologyShizuoka Cancer CenterSunto-gunJapan
  12. 12.Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
  13. 13.Department of SurgeryKeio University School of MedicineTokyoJapan

Personalised recommendations